[SCHEDULE 13G/A] Akero Therapeutics, Inc. SEC Filing
Janus Henderson Group plc reported beneficial ownership of 6,738,556 ordinary shares of Akero Therapeutics, representing 8.5% of the class, and disclosed shared voting and dispositive power over those shares while reporting no sole voting or dispositive power.
The filing also states that JHIUS may be deemed the beneficial owner of 6,654,976 shares (8.4%) and identifies JHIUS, JHIUKL and JHIAIFML as indirect subsidiaries that are registered investment advisers advising Managed Portfolios. Janus Henderson certifies these holdings are held in the ordinary course of business and were not acquired to change or influence control.
Janus Henderson Group plc ha segnalato la titolarit脿 effettiva di 6.738.556 azioni ordinarie di Akero Therapeutics, pari al 8,5% della classe, indicando potere di voto e dispositivo condiviso su tali azioni e dichiarando di non possedere potere di voto o dispositivo esclusivo.
Il deposito indica inoltre che JHIUS pu貌 essere considerato il beneficiario effettivo di 6.654.976 azioni (8,4%) e identifica JHIUS, JHIUKL e JHIAIFML come societ脿 controllate indirette che sono consulenti di investimento registrati e gestiscono portafogli. Janus Henderson certifica che queste partecipazioni sono detenute nell'ambito ordinario dell'attivit脿 e non sono state acquisite con l'intento di modificare o influenzare il controllo.
Janus Henderson Group plc inform贸 la propiedad beneficiaria de 6.738.556 acciones ordinarias de Akero Therapeutics, que representan el 8,5% de la clase, y comunic贸 tener poder de voto y dispositivo compartido sobre esas acciones, al tiempo que declar贸 no poseer poder de voto o dispositivo exclusivo.
La presentaci贸n tambi茅n indica que JHIUS puede considerarse beneficiario efectivo de 6.654.976 acciones (8,4%) e identifica a JHIUS, JHIUKL y JHIAIFML como filiales indirectas que son asesores de inversi贸n registrados que gestionan carteras. Janus Henderson certifica que estas tenencias se mantienen en el curso ordinario del negocio y no fueron adquiridas para cambiar o influir en el control.
Janus Henderson Group plc電� Akero Therapeutics鞚� 6,738,556 氤错喌欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨柎 頃措嫻 膦呺鞚� 8.5%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨溂氅�, 頃措嫻 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃滊嫟瓿� 瓿店皽頃橁碃 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 氤挫湢頃橃 鞎婋姅雼り碃 氤搓碃頄堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 JHIUS臧� 6,654,976欤�(8.4%)鞚� 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅� 靾� 鞛堨溂氅� JHIUS, JHIUKL 氚� JHIAIFML鞚� 霌彪霅� 韴瀽鞛愲靷靹� 鞖挫毄 韽姼韽措Μ鞓るゼ 鞛愲頃橂姅 臧勳爲 鞛愴殞靷 鞁濍硠頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Janus Henderson電� 鞚措煬頃� 氤挫湢臧� 鞓侅梾鞚� 韱奠儊鞝侅澑 氩旍渼 雮挫棎靹� 氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Janus Henderson Group plc a d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 6 738 556 actions ordinaires d'Akero Therapeutics, repr茅sentant 8,5 % de la cat茅gorie, et a indiqu茅 d茅tenir un pouvoir de vote et de disposition partag茅 sur ces actions, tout en pr茅cisant ne pas avoir de pouvoir de vote ou de disposition exclusif.
Le d茅p么t pr茅cise 茅galement que JHIUS peut 锚tre consid茅r茅 comme propri茅taire b茅n茅ficiaire de 6 654 976 actions (8,4 %) et identifie JHIUS, JHIUKL et JHIAIFML comme des filiales indirectes qui sont des conseillers en investissement enregistr茅s conseillant des portefeuilles g茅r茅s. Janus Henderson certifie que ces participations sont d茅tenues dans le cours normal de son activit茅 et n'ont pas 茅t茅 acquises en vue de modifier ou d'influencer le contr么le.
Janus Henderson Group plc meldete wirtschaftliches Eigentum an 6.738.556 Stammaktien von Akero Therapeutics, was 8,5% der Klasse entspricht, und gab an, 眉ber diese Aktien gemeinsames Stimm- und Verf眉gungsrecht zu haben, w盲hrend kein alleiniges Stimm- oder Verf眉gungsrecht besteht.
Die Einreichung besagt au脽erdem, dass JHIUS als wirtschaftlicher Eigent眉mer von 6.654.976 Aktien (8,4%) angesehen werden kann, und identifiziert JHIUS, JHIUKL und JHIAIFML als indirekte Tochtergesellschaften, die als registrierte Anlageberater Managed Portfolios betreuen. Janus Henderson best盲tigt, dass diese Best盲nde im gew枚hnlichen Gesch盲ftsbetrieb gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle erworben wurden.
- Reported aggregate beneficial ownership of 6,738,556 shares, representing 8.5% of the class
- Disclosed shared voting and shared dispositive power over the reported shares, with 0 sole voting or dispositive power stated
- Identified indirect subsidiaries (JHIUS, JHIUKL, JHIAIFML) as registered investment advisers advising Managed Portfolios, clarifying ownership channels
- Filing includes a certification that the securities are held in the ordinary course of business and not to influence control
- The filing contains two different reported beneficial-ownership figures: 6,738,556 shares (8.5%) aggregated and 6,654,976 shares (8.4%) attributed to JHIUS, which requires reconciliation
Insights
TL;DR Significant institutional stake reported: >5% ownership with shared voting/dispositive power; filing asserts passive/ordinary-course holding.
Janus Henderson's reported aggregate position of 6,738,556 shares (8.5%) represents a material disclosure under Schedule 13G standards and is large enough to be relevant to owners and analysts tracking institutional concentration. The filing documents shared voting and dispositive power rather than sole control, and it explicitly states the securities are held in the ordinary course of business and not to influence control. The filing also names registered-adviser subsidiaries that advise Managed Portfolios, which clarifies ownership channels. Investors should note the separate subsidiary figure of 6,654,976 shares (8.4%) reported for JHIUS within the same filing as an item requiring reconciliation within the record.
TL;DR Report discloses material passive stake and adviser-held positions; governance impact appears limited per certification in the filing.
The Schedule 13G/A identifies Janus Henderson as holding a material stake without claiming sole voting or dispositive authority, which the filer certifies is not intended to change or influence issuer control. The filing further identifies named indirect subsidiaries (JHIUS, JHIUKL, JHIAIFML) that are registered investment advisers to Managed Portfolios, explaining the likely chain of custody. A power of attorney is included for representatives to file required reports. From a governance perspective, the disclosure documents material ownership while explicitly asserting passive intent, limiting immediate control implications based solely on this filing.
Janus Henderson Group plc ha segnalato la titolarit脿 effettiva di 6.738.556 azioni ordinarie di Akero Therapeutics, pari al 8,5% della classe, indicando potere di voto e dispositivo condiviso su tali azioni e dichiarando di non possedere potere di voto o dispositivo esclusivo.
Il deposito indica inoltre che JHIUS pu貌 essere considerato il beneficiario effettivo di 6.654.976 azioni (8,4%) e identifica JHIUS, JHIUKL e JHIAIFML come societ脿 controllate indirette che sono consulenti di investimento registrati e gestiscono portafogli. Janus Henderson certifica che queste partecipazioni sono detenute nell'ambito ordinario dell'attivit脿 e non sono state acquisite con l'intento di modificare o influenzare il controllo.
Janus Henderson Group plc inform贸 la propiedad beneficiaria de 6.738.556 acciones ordinarias de Akero Therapeutics, que representan el 8,5% de la clase, y comunic贸 tener poder de voto y dispositivo compartido sobre esas acciones, al tiempo que declar贸 no poseer poder de voto o dispositivo exclusivo.
La presentaci贸n tambi茅n indica que JHIUS puede considerarse beneficiario efectivo de 6.654.976 acciones (8,4%) e identifica a JHIUS, JHIUKL y JHIAIFML como filiales indirectas que son asesores de inversi贸n registrados que gestionan carteras. Janus Henderson certifica que estas tenencias se mantienen en el curso ordinario del negocio y no fueron adquiridas para cambiar o influir en el control.
Janus Henderson Group plc電� Akero Therapeutics鞚� 6,738,556 氤错喌欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨柎 頃措嫻 膦呺鞚� 8.5%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨溂氅�, 頃措嫻 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃滊嫟瓿� 瓿店皽頃橁碃 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 氤挫湢頃橃 鞎婋姅雼り碃 氤搓碃頄堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 JHIUS臧� 6,654,976欤�(8.4%)鞚� 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅� 靾� 鞛堨溂氅� JHIUS, JHIUKL 氚� JHIAIFML鞚� 霌彪霅� 韴瀽鞛愲靷靹� 鞖挫毄 韽姼韽措Μ鞓るゼ 鞛愲頃橂姅 臧勳爲 鞛愴殞靷 鞁濍硠頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Janus Henderson電� 鞚措煬頃� 氤挫湢臧� 鞓侅梾鞚� 韱奠儊鞝侅澑 氩旍渼 雮挫棎靹� 氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Janus Henderson Group plc a d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 6 738 556 actions ordinaires d'Akero Therapeutics, repr茅sentant 8,5 % de la cat茅gorie, et a indiqu茅 d茅tenir un pouvoir de vote et de disposition partag茅 sur ces actions, tout en pr茅cisant ne pas avoir de pouvoir de vote ou de disposition exclusif.
Le d茅p么t pr茅cise 茅galement que JHIUS peut 锚tre consid茅r茅 comme propri茅taire b茅n茅ficiaire de 6 654 976 actions (8,4 %) et identifie JHIUS, JHIUKL et JHIAIFML comme des filiales indirectes qui sont des conseillers en investissement enregistr茅s conseillant des portefeuilles g茅r茅s. Janus Henderson certifie que ces participations sont d茅tenues dans le cours normal de son activit茅 et n'ont pas 茅t茅 acquises en vue de modifier ou d'influencer le contr么le.
Janus Henderson Group plc meldete wirtschaftliches Eigentum an 6.738.556 Stammaktien von Akero Therapeutics, was 8,5% der Klasse entspricht, und gab an, 眉ber diese Aktien gemeinsames Stimm- und Verf眉gungsrecht zu haben, w盲hrend kein alleiniges Stimm- oder Verf眉gungsrecht besteht.
Die Einreichung besagt au脽erdem, dass JHIUS als wirtschaftlicher Eigent眉mer von 6.654.976 Aktien (8,4%) angesehen werden kann, und identifiziert JHIUS, JHIUKL und JHIAIFML als indirekte Tochtergesellschaften, die als registrierte Anlageberater Managed Portfolios betreuen. Janus Henderson best盲tigt, dass diese Best盲nde im gew枚hnlichen Gesch盲ftsbetrieb gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle erworben wurden.
FAQ
How many AKRO shares does Janus Henderson report owning?
What voting and dispositive power does Janus Henderson report over AKRO shares?
Is this stake held to influence control of Akero Therapeutics (AKRO)?
Which subsidiaries are identified as holding or advising on the AKRO position?
Does the filing include authorization for filings on behalf of Janus Henderson?
